Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
DERM
DERM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DERM News
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Nov 13 2025
NASDAQ.COM
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
Oct 24 2025
Newsfilter
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Oct 24 2025
NASDAQ.COM
HC Wainwright & Co. Begins Coverage of Journey Medical with a Buy Rating and Sets Price Target at $13
Aug 25 2025
Benzinga
Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open
Aug 18 2025
Globenewswire
Journey Medical Corporation to Showcase at the Emerging Growth Conference
Aug 18 2025
Newsfilter
CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Aug 13 2025
Benzinga
Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
Aug 13 2025
Benzinga
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
Aug 07 2025
Newsfilter
B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $12
Jul 30 2025
Benzinga
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Jul 14 2025
Newsfilter
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
Jun 24 2025
Newsfilter
Journey Medical to join Russell 2000 and 3000 Indexes
Jun 24 2025
SeekingAlpha
Journey Medical Corporation Announces Emrosi™ Featured on "The Balancing Act" Airing on Lifetime TV
Jun 09 2025
Newsfilter
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 15 2025
Newsfilter
Journey Medical Narrows Q1 Loss, Launches Emrosi With Early Revenue And Strong Clinical Backing
May 15 2025
NASDAQ.COM
Show More News
